Welcome to our dedicated page for Mynd Life Scienc news (Ticker: MYNDF), a resource for investors and traders seeking the latest updates and insights on Mynd Life Scienc stock.
MYND Life Sciences Inc. (MYNDF) is a clinical-stage biotechnology company advancing innovative diagnostic tools and therapies for depression treatment. This page serves as the definitive source for official news and press releases related to their biomarker development programs, neuropharmaceutical research, and corporate developments.
Investors and researchers will find timely updates on key initiatives including the MYND Anti-Inflammatory Peptide (MAP) diagnostic test, psilocybin-based therapeutic research, and strategic financial management activities. The curated news collection provides essential insights into clinical trial progress, intellectual property advancements, and partnership announcements.
All content undergoes rigorous verification to ensure accuracy and compliance with financial disclosure standards. Regular updates cover material developments across three core areas: diagnostic biomarker validation, drug candidate research, and balance sheet optimization strategies.
Bookmark this page for direct access to primary source information about MYNDF's progress in developing precision medicine solutions for neuropsychiatric disorders. Check back regularly for verified updates that matter to stakeholders in the life sciences investment community.
MYND Diagnostics has announced its involvement in a $3 million clinical trial funded by the Government of Australia, aimed at evaluating psilocybin-assisted psychotherapy for treatment-resistant depression. The trial will employ MYND's proprietary biomarkers to monitor patient responses and progress. Conducted by Dr. Paul Fitzgerald at Monash University, this phase 2b trial could lead to a multi-site phase 3 trial within a year, paving the way for potential regulatory approval by the Therapeutic Goods Association. MYND also anticipates entering more clinical trials in 2022/2023 to advance its biomarker development.
MYND Life Sciences Inc. has entered a Collaborative Research Agreement with the University of British Columbia to explore novel therapies for neurological diseases. The focus is on developing precision medicines, particularly those involving Psilocybins, aimed at improving treatment outcomes for conditions like dementia.
MYND is advancing various clinical programs, including a pivotal trial for novel biomarkers for treatment-resistant depression, with plans for additional clinical trials in 2022/2023. The company also announced the departure of COO Jordan Cleland, with Dr. Chahaat Singh assuming operational responsibilities.
MYND Life Sciences has completed the acquisition of intellectual property rights to use psychedelics for treating dementia, including Alzheimer's disease, from Cava Healthcare. This acquisition is expected to enhance MYND's capabilities in psilocybin-assisted therapy, which is aimed at addressing a condition that affects 44 to 50 million people globally. MYND issued 450,000 shares at $0.85 each and made a cash payment of $120,000. An annual royalty of $240,000 or 4% of net sales will also be paid. The acquisition positions MYND as a leader in psychedelic therapeutics for dementia.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announced the completion of its National Phase filing for a Patent Cooperation Treaty (PCT) application related to a method of immune modulation targeting a specific gene. CEO Dr. Lyle Oberg stated that building a solid intellectual property portfolio is crucial for long-term shareholder value. The PCT enables simultaneous patent protection across multiple countries. MYND aims to advance its drug pipeline to file for Innovative New Drug (IND) application. The company has also engaged Hybrid Financial Ltd. for marketing services.
MYND Life Sciences has received a grant of $45,600 from the Government of Canada to support research on the effects of psilocybin in treating brain diseases. The funding will aid a project titled Phytochemical-analog(s) as a novel method for management of treatment-resistant depression, running from November 2021 to March 2022. The project aims to explore how psilocybin analogs can modulate brain function by targeting specific gene pathways. The company is committed to advancing neuro-pharmaceutical innovations.
MYND Diagnostics, a subsidiary of MYND Life Sciences, has launched a clinical validation study for its proprietary MAP biomarker test aimed at aiding the diagnosis and monitoring of Multiple Sclerosis (MS). The study, expected to start in Q1 2022, will quantify MAP levels in MS patients' blood samples compared to controls. Successful results could lead to an FDA approval submission in H2 2022, making the test available through healthcare providers. The global MS therapeutic market was valued at $22.99 billion in 2018 and is projected to reach $28 billion by 2026.
MYND Life Sciences has announced the initiation of a clinical validation study for its proprietary biomarker testing in Alzheimer's Disease (AD) diagnostics. The study, conducted by its subsidiary MYND Diagnostics, aims to utilize the MAP biomarker to enhance early diagnosis and monitoring of AD. The validation is set to commence in Q1 2022, with anticipated FDA submission for approval in H2 2022. Currently, around 44 million people are affected by AD worldwide, and the diagnostics market was valued at USD 6.6 billion in 2020, projected to reach USD 9 billion by 2026.
